Harvard University launched a study that found that people taking semaglutide were four to nearly eight times more likely to develop nonarteritic anterior ischemic optic neuropathy (NAION) than their peers on other non-GLP-1 meds for diabetes and weight loss.

The Judicial Panel on Multidistrict Litigation has reassigned the Ozempic and Mounjaro multidistrict litigation (MDL) cases to Judge Karen S. Marston after the passing of Judge Gene E. K. Pratter.

Eli Lilly, the maker of Mounjaro, has sued wellness centers and medical spas for illegally producing and selling fake versions of their GLP-1 medications and weight loss drugs.